Suchergebnisse - "Brightling, Christopher E"

PubPharm (19)

1

Biomarkers Associated with Lung Function Decline and Dupilumab Response in Patients with Asthma

enthalten in: American journal of respiratory and critical care medicine | 2024

von Pavord, I. | De Prado Gómez, L. | Brusselle, G. | +15

2

Dupilumab in type 2 airway inflammation-a step forward in targeted therapy for COPD

enthalten in: The Journal of allergy and clinical immunology | 2024

von Tan, R. | Aung, H. | Flynn, C. | +2

3

Tezepelumab and Mucus Plugs in Patients with Moderate-to-Severe Asthma

enthalten in: NEJM evidence | 2023

von Nordenmark, L. | Hellqvist, �. | Emson, C. | +10

4

Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION) : a randomised, placebo-controlled extension study

enthalten in: The Lancet. Respiratory medicine | 2023

von Menzies-Gow, A. | Wechsler, M. | Brightling, C. | +114

CommentIn: Lancet Respir Med. 2023 Jan 23;:. - PMID 36702145

5

Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE) : a randomised, placebo-controlled, phase 3 study

enthalten in: The Lancet. Respiratory medicine | 2022

von Wechsler, M. | Menzies-Gow, A. | Brightling, C. | +72

ErratumIn: Lancet Respir Med. 2022 Apr 5;:. - PMID 35395206

6

Astegolimab, an anti-ST2, in chronic obstructive pulmonary disease (COPD-ST2OP) : a phase 2a, placebo-controlled trial

enthalten in: The Lancet. Respiratory medicine | 2022

von Yousuf, A. | Mohammed, S. | Carr, L. | +21

CommentIn: Lancet Respir Med. 2022 May;10(5):425-426. - PMID 35339232

7

Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE) : a double-blind, randomised, placebo-controlled, phase 2 trial

enthalten in: The Lancet. Respiratory medicine | 2021

von Diver, S. | Khalfaoui, L. | Emson, C. | +10

ErratumIn: Lancet Respir Med. 2021 Nov;9(11):e106. - PMID 34739888

8

The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study) : a prospective observational study

enthalten in: The Lancet. Respiratory medicine | 2021

von McDowell, P. | Diver, S. | Yang, F. | +41

9

Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma : A randomized clinical trial

enthalten in: The Journal of allergy and clinical immunology | 2021

von Kelsen, S. | Agache, I. | Soong, W. | +12

CommentIn: J Allergy Clin Immunol. 2021 Sep;148(3):719-721. - PMID 34310926

10

Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma

enthalten in: The New England journal of medicine | 2021

von Menzies-Gow, A. | Corren, J. | Bourdin, A. | +11

CommentIn: Ann Intern Med. 2021 Oct;174(10):JC115. - PMID 34606305